Key result
This narrative review explores the potential of the phosphodiesterase-4 inhibitor roflumilast to protect against renal dysfunction, inflammation, and apoptosis in sepsis-induced acute kidney injury.
Why the study?
Roflumilast may help reverse sepsis-induced liver and lung damage, but whether it is effective in reversing sepsis-induced renal impairment remains unknown.
Does roflumilast protect against renal dysfunction, inflammatory response, and apoptosis in sepsis-induced kidney damage?
Does roflumilast protect against renal dysfunction, inflammatory response, and apoptosis in sepsis-induced kidney damage?
This narrative review explores the potential of roflumilast, a PDE-4 inhibitor, to protect against renal dysfunction, inflammation, and apoptosis in sepsis-induced acute kidney injury.
Hypothesis-generating for roflumilast in sepsis-AKI; prospective trials needed before clinical consideration.
Severe infections such as viral, bacterial, or fungal sepsis can cause an inflammatory response in the host, leading to organ failure and septic shock-phosphodiesterase-4 (PDE-4) inhibiting related agents from suppressing cyclic adenosine monophosphate (cAMP) degradation. Regulatory organisations have approved some substances in this category to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with chronic bronchitis and a history of COPD exacerbations. Roflumilast has been shown to alleviate inflammatory responses, thus regulating airway inflammation. Additionally, roflumilast therapy dramatically enhanced B-cell lymphoma 2 (Bcl-2) expression, an anti-apoptotic marker lowered in septic animals. Previous research has indicated that roflumilast may help reverse sepsis-induced liver and lung harm, but whether it is also effective in reversing sepsis-induced renal impairment remains unknown. Therefore, this review determines whether roflumilast protects against renal dysfunction, inflammatory response, and apoptosis in sepsis-induced kidney damage. Additionally, we discussed the molecular mechanism through which roflumilast exerts its protective effect to uncover a possible treatment agent for sepsis-induced renal impairment.
No takes yet. Share an insight, caveat, or question.
Kazmi et al. (2022) conducted a review in Sepsis-induced acute kidney injury. Roflumilast was evaluated on Renal dysfunction, inflammatory response, and apoptosis. This narrative review explores the potential of the phosphodiesterase-4 inhibitor roflumilast to protect against renal dysfunction, inflammation, and apoptosis in sepsis-induced acute kidney injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: